Display options
Cite
Haapaniemi TH, Korpelainen JT, Tolonen U, et al. Suppressed sympathetic skin response in Parkinson disease. Clin Auton Res. 2000;10(6):337-42doi: 10.1007/BF02322257.
Haapaniemi, T. H., Korpelainen, J. T., Tolonen, U., Suominen, K., Sotaniemi, K. A., & Myllylä, V. V. (2000). Suppressed sympathetic skin response in Parkinson disease. Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 10(6), 337-42. https://doi.org/10.1007/BF02322257
Haapaniemi, T H, et al. "Suppressed sympathetic skin response in Parkinson disease." Clinical autonomic research : official journal of the Clinical Autonomic Research Society vol. 10,6 (2000): 337-42. doi: https://doi.org/10.1007/BF02322257
Haapaniemi TH, Korpelainen JT, Tolonen U, Suominen K, Sotaniemi KA, Myllylä VV. Suppressed sympathetic skin response in Parkinson disease. Clin Auton Res. 2000 Dec;10(6):337-42. doi: 10.1007/BF02322257. PMID: 11324989.
Copy Download .nbib Format: NLM
Share it on

Clin Auton Res. 2000 Dec;10(6):337-42. doi: 10.1007/BF02322257.

Suppressed sympathetic skin response in Parkinson disease.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society

T H Haapaniemi, J T Korpelainen, U Tolonen, K Suominen, K A Sotaniemi, V V Myllylä

Affiliations

  1. Department of Neurology, University of Oulu, Finland. [email protected]

PMID: 11324989 DOI: 10.1007/BF02322257

Abstract

The sympathetic skin response (SSR) was used to evaluate sympathetic sudomotor activity in Parkinson disease (PD) and the effects of antiparkinsonian medication on the disease. We recorded SSRs to electric and auditory stimulation in 58 untreated patients with PD and in 20 healthy controls. In addition to amplitude and latency measurements, we examined the number of SSRs evoked by a single stimulus and the response adaptation after repetitive stimuli. The patients with PD subsequently were randomized for administration of levodopa/ carbidopa (n = 19), bromocriptine (n = 20), or selegiline (n = 19) as their initial treatment. The measurements were repeated after 6 months of medication and after a washout period. SSR amplitudes were significantly lower in patients with PD than in the control subjects at baseline. The amplitude reduction was more pronounced in patients with high Unified Parkinson's Disease Rating Scale scores, in those with high tremor scores, and in those with PD symptoms that had lasted more than 1 year. The levodopa/carbidopa and bromocriptine treatments did not influence SSRs, although selegiline slightly decreased the amplitude. The synchronous responses after a single stimulus were more often repetitive in the patients with PD than in the controls, although the response adaptation tendencies were similar. In conclusion, the degenerative process in PD involves the sudomotor system as reflected by the progressive suppression of SSR amplitudes with a correlation to PD symptom duration and clinical disability, whereas PD medications seems to have only minor effects. The changes in amplitude and the repetitiveness of SSRs with normal adaptation may be caused by deficits at several levels of the SSR reflex arch.

References

  1. Acta Neurol Scand. 1997 May;95(5):293-7 - PubMed
  2. Neurology. 1967 May;17(5):427-42 - PubMed
  3. Acta Neurol Scand. 1995 May;91(5):372-6 - PubMed
  4. Muscle Nerve. 1995 Aug;18(8):917-9 - PubMed
  5. Ann Neurol. 1978 Feb;3(2):129-33 - PubMed
  6. J Physiol. 1980 Sep;306:537-52 - PubMed
  7. J Neurol. 1994 Oct;241(10):573-6 - PubMed
  8. Eur Neurol. 1992;32(3):134-40 - PubMed
  9. Clin Neurol Neurosurg. 1988;90(3):221-6 - PubMed
  10. Acta Neurol Scand. 1996 Feb-Mar;93(2-3):127-32 - PubMed
  11. Electromyogr Clin Neurophysiol. 1989 Apr;29(3):155-9 - PubMed
  12. J Neurol Neurosurg Psychiatry. 1976 Nov;39(11):1092-100 - PubMed
  13. Neurology. 1986 Jan;36(1):73-5 - PubMed
  14. Muscle Nerve. 1987 Oct;10(8):711-6 - PubMed
  15. Acta Neurol Scand. 1995 Feb;91(2):98-102 - PubMed
  16. J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):902-8 - PubMed
  17. J Neurol Sci. 1988 Nov;87(2-3):299-306 - PubMed
  18. Lancet. 1972 Jan 22;1(7743):174-6 - PubMed
  19. Arch Neurol. 1990 Jun;47(6):659-64 - PubMed
  20. J Neurol Neurosurg Psychiatry. 1993 Oct;56(10):1090-5 - PubMed
  21. Brain. 1991 Jun;114 ( Pt 3):1381-94 - PubMed
  22. Clin Auton Res. 1999 Feb;9(1):17-22 - PubMed
  23. Muscle Nerve. 1988 Mar;11(3):261-4 - PubMed
  24. J Neurol Sci. 1980 Sep;47(3):433-48 - PubMed
  25. Stroke. 1993 Sep;24(9):1389-92 - PubMed
  26. J Comp Physiol Psychol. 1969 Nov;69(3):465-72 - PubMed
  27. Eur Neurol. 1987;26(2):104-12 - PubMed
  28. Adv Neurol. 1990;53:463-8 - PubMed
  29. Muscle Nerve. 1991 Nov;14(11):1074-9 - PubMed
  30. J Neurol. 1991 Jul;238(4):195-9 - PubMed
  31. Mov Disord. 1996 May;11(3):268-72 - PubMed
  32. Mov Disord. 1993 Apr;8(2):151-7 - PubMed
  33. Clin Neurophysiol. 1999 Feb;110(2):358-66 - PubMed
  34. J Neurol Neurosurg Psychiatry. 1984 May;47(5):536-42 - PubMed
  35. Electroencephalogr Clin Neurophysiol. 1990 Sep;76(3):258-67 - PubMed
  36. Acta Neurol Scand. 1992 Apr;85(4):272-5 - PubMed
  37. Muscle Nerve. 1988 Feb;11(2):183-4 - PubMed
  38. Adv Neurol. 1993;60:609-12 - PubMed

Substances

MeSH terms

Publication Types